Nuclear IGF-1R predicts chemotherapy and targeted therapy resistance in metastatic colorectal cancer

BACKGROUND: Although chemotherapy is the cornerstone treatment for patients with metastatic colorectal cancer (mCRC), acquired chemoresistance is common and constitutes the main reason for treatment failure. Monoclonal antibodies against insulin-like growth factor-1 receptor (IGF-1R) have been teste...

Descripción completa

Detalles Bibliográficos
Autores principales: Codony-Servat, Jordi, Cuatrecasas, Miriam, Asensio, Elena, Montironi, Carla, Martínez-Cardús, Anna, Marín-Aguilera, Mercedes, Horndler, Carlos, Martínez-Balibrea, Eva, Rubini, Michele, Jares, Pedro, Reig, Oscar, Victoria, Iván, Gaba, Lydia, Martín-Richard, Marta, Alonso, Vicente, Escudero, Pilar, Fernández-Martos, Carlos, Feliu, Jaime, Méndez, Jose Carlos, Méndez, Miguel, Gallego, Javier, Salud, Antonieta, Rojo, Federico, Castells, Antoni, Prat, Aleix, Rosell, Rafael, García-Albéniz, Xabier, Camps, Jordi, Maurel, Joan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2017
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5729466/
https://www.ncbi.nlm.nih.gov/pubmed/29123263
http://dx.doi.org/10.1038/bjc.2017.279

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5729466/
https://www.ncbi.nlm.nih.gov/pubmed/29123263
http://dx.doi.org/10.1038/bjc.2017.279

Ejemplares similares